Conditioned place preference studies with atomoxetine in an animal model of ADHD: Effects of previous atomoxetine treatment
-
Add time:07/22/2019 Source:sciencedirect.com
To investigate the putative rewarding effects of atomoxetine, a non-stimulant medication for Attention-deficit/hyperactivity disorder (ADHD), we conducted conditioned place preference (CPP) tests in an animal model of ADHD, the spontaneously hypertensive rat (SHR). The effects of drug pre-exposure were also evaluated, thus, parallel experiments were done in rats which have undergone 14 days of atomoxetine treatment. The responses of SHR were compared with the rat strain representing the “normal” heterogeneous population, the Wistar rats. Neither rat strain showed significant CPP to atomoxetine. However, previous atomoxetine treatment produced place preference responses in rats, more profoundly in Wistar rats conditioned with the low and moderate atomoxetine doses. In conclusion, acute exposure to atomoxetine does not have any rewarding effect, however, drug pretreatment produces responses characteristic of reward or psychological dependence, more specifically in the “normal” vs. the ADHD animal model. The present findings call for more studies with atomoxetine, especially those that investigate the effects of long-term or chronic drug treatment.
► Acute exposure to atomoxetine has no rewarding effects. ► Repeated atomoxetine treatment produces psychological dependence to the drug. ► The rewarding effect is more profound in the Wistar vs. SHR.
We also recommend Trading Suppliers and Manufacturers of Atomoxetine hydrochloride (cas 82248-59-7). Pls Click Website Link as below: cas 82248-59-7 suppliers
Prev:Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson’s disease
Next:Changes in serum miRNA-let-7 level in children with attention deficit hyperactivity disorder treated by repetitive transcranial magnetic stimulation or atomoxetine: An exploratory trial) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor ‘knockout’ mice07/24/2019
- Changes in serum miRNA-let-7 level in children with attention deficit hyperactivity disorder treated by repetitive transcranial magnetic stimulation or atomoxetine: An exploratory trial07/23/2019
- Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson’s disease07/20/2019
- Atomoxetine hydrochloride (cas 82248-59-7) in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study07/21/2019
- Determination of the enantiomer and positional isomer impurities in Atomoxetine hydrochloride (cas 82248-59-7) with liquid chromatography using polysaccharide chiral stationary phases07/19/2019
- Atomoxetine, a selective norepinephrine reuptake inhibitor, improves short-term histological outcomes after hypoxic-ischemic brain injury in the neonatal male rat07/18/2019
- Atomoxetine prevents working memory loss in hyperactive rats, mediating plastic changes in prefrontal cortex pyramidal neurons07/17/2019
- Atomoxetine hydrochloride (cas 82248-59-7) for the treatment of attention-deficit/hyperactivity disorder07/16/2019
- A quality by design approach to impurity method development for Atomoxetine hydrochloride (cas 82248-59-7) (LY139603)07/15/2019
-
Health and Chemical more >